Sickle Cell Disease: Clinical Trials

26 trials for Sickle Cell Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 4 terminated, 3 withdrawn, 2 not yet recruiting. 26 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 426Completed 12, Terminated 4, Withdrawn 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Unknown 1

Follow Sickle Cell Disease: new trials by email Literature Review of Sickle Cell Disease trials Research Report on Sickle Cell Disease

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis
Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 4Not yet recruitingAssistance Publique - Hôpitaux de Paris4002026-10-012026-09-18
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related
Phase 4WithdrawnEmory University2026-09-012026-10-19
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Ketorolac - Sickle Cell Disease, Sickle Cell Crisis
Phase 4Not yet recruitingChildren's Blood and Cancer Center at Dell Children's Medical Center1022024-09-302024-08-30
Stroke Prevention in Nigeria 2 Trial
Hydroxyurea - Sickle Cell Disease, Stroke
Phase 4RecruitingVanderbilt University Medical Center2202024-08-052026-03-05
Voxelotor Brain Oxygenation and Neurocognitive Study
Voxelotor Oral Tablet - Sickle Cell Disease
Phase 4WithdrawnPfizer2023-08-092024-08-09
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Nexplanon 68 MG Drug Implant - Sickle Cell Disease
Phase 4Active not recruitingUniversity of Pennsylvania222023-08-022026-06-12
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Mitapivat - Pyruvate Kinase Deficiency, Anemia, Hemolytic
Phase 4Enrolling by invitationAgios Pharmaceuticals, Inc.552023-07-062026-10-28
Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient
Clonidine - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease
Phase 4UnknownCentre Hospitalier Universitaire Saint Pierre402023-04-252023-05-08
Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
L-Glutamine, Oral Powder for Reconstitution, Standard of care - Sickle Cell Disease
Phase 4CompletedAin Shams University602022-01-042024-01-09
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Crizanlizumab - Sickle Cell Disease
Phase 4RecruitingNovartis Pharmaceuticals1302021-06-102026-06-08
Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients
L-glutamine - Sickle Cell Disease, Pharmacokinetics
Phase 4CompletedEmmaus Medical, Inc.132021-01-042022-08-02
Actigraphy Improvement With Voxelotor (ActIVe) Study
Voxelotor - Sickle Cell Disease, Sickle Cell Anemia
Phase 4CompletedPfizer252020-12-212023-11-21
Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia
Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine, Hydroxycarbamide 500 Mg Oral Capsule, L-Carnitine, 250 Mg Oral Capsule - Sickle Cell Disease
Phase 4CompletedAssiut University912017-01-102021-10-22
Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions
Rejuvesol, Blood transfusion - Sickle Cell Disease
Phase 4CompletedDuke University42016-12-012019-01-25
Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients
Vitamin E - Sickle Cell Disease
Phase 4CompletedAin Shams University502016-06-012023-05-03
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
Siklos - Sickle Cell Disease, Renal Function Disorder
Phase 4CompletedTheravia402015-09-032021-10-12
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Deferiprone - Iron Overload, Sickle Cell Disease
Phase 4TerminatedApoPharma1342015-05-212024-01-10
Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease
Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing) - Sickle Cell Disease
Phase 4CompletedDuke University1062015-03-152017-08-04
Contraception in Women With Sickle Cell Disease
etonogestrel-releasing implant contraceptive - Sickle Cell Disease
Phase 4CompletedUniversity of Sao Paulo292015-01-012020-11-06
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
hydroxyurea - Sickle Cell Disease, Sickle Cell Anemia
Phase 4CompletedLoyola University532014-12-012023-03-09

Showing 20 of 26. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (26)  ·  Vaso-Occlusive Crises (4)  ·  Agnosia (3)  ·  Iron Overload (2)  ·  Pain (2)  ·  Thalassemia (2)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Emergencies (1)  ·  Pyruvate Kinase Deficiency of Red Cells (1)  ·  Stroke (1)  ·  beta-Thalassemia (1)

Broader conditions

Anemia, Hemolytic, Congenital (26)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26)  ·  Genetic Diseases, Inborn (26)  ·  Hematologic Diseases (26)  ·  Hemic and Lymphatic Diseases (26)  ·  Hemoglobinopathies (26)  ·  Anemia (25)  ·  Anemia, Hemolytic (25)  ·  Nervous System Diseases (4)  ·  Neurologic Manifestations (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Neurobehavioral Manifestations (3)  ·  Perceptual Disorders (3)  ·  Iron Metabolism Disorders (2)

Interventions

Morphine (5)  ·  Hydroxyurea (4)  ·  Deferiprone (2)  ·  Deferoxamine (2)  ·  Glutamine (2)  ·  Ketamine (2)  ·  etonogestrel (2)  ·  voxelotor (2)  ·  Antioxidants (1)  ·  Blood Transfusion (1)  ·  Carnitine (1)  ·  Clonidine (1)  ·  Codeine (1)  ·  Control Groups (1)  ·  Deferasirox (1)

Sponsors

Ain Shams University (2)  ·  ApoPharma (2)  ·  Duke University (2)  ·  Pfizer (2)  ·  Agios Pharmaceuticals, Inc. (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Assiut University (1)  ·  Boston Children's Hospital (1)  ·  Centre Hospitalier Universitaire Saint Pierre (1)  ·  Children's Blood and Cancer Center at Dell Children's Medical Center (1)  ·  Children's Hospital of Philadelphia (1)  ·  Children's National Research Institute (1)  ·  Emmaus Medical, Inc. (1)  ·  Emory University (1)  ·  London North West Healthcare NHS Trust (1)

Countries

United States (13)  ·  Brazil (4)  ·  Egypt (4)  ·  United Kingdom (4)  ·  Belgium (3)  ·  Canada (3)  ·  France (3)  ·  Turkey (Türkiye) (3)  ·  Nigeria (2)  ·  Saudi Arabia (2)  ·  Colombia (1)  ·  Germany (1)  ·  Ireland (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Fatma SE Ebeid, MD (2)  ·  Janet Kwiatkowski, MD (2)  ·  Alicia Chang, MD (1)  ·  Arjunan Ganesh, MD (1)  ·  Bamidele O Tayo, PhD (1)  ·  Caroline Dore, BSc (1)  ·  Deborah Chirnomas, MD (1)  ·  Gavin Cho, MD (1)  ·  Ian J Welsby, BSc MBBS (1)  ·  Israa EM Ashry, Prof (1)  ·  Jay Raval, MD (1)  ·  Julia C. Finkel, M.D. (1)  ·  Kofi A Anie, PhD (1)

Results publications

PMID 10100293, PMID 19724055, PMID 2082307, PMID 2666928, PMID 2689472, PMID 27288381, PMID 27993418, PMID 28238158, PMID 29756251, PMID 30663794, PMID 34847228, PMID 36018224, PMID 37807937, PMID 37975597, PMID 38401036, PMID 9620101

NIH funding

U01NS129143 (1)